Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DN052 combined with toripalimab in advanced solid tumors
ChiCTR2200064196Phase 2Not yet recruiting
- Sponsor
- Peking University Cancer Hospital & Institute
- Start
- Sep 2021
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of DN1508052 and toripalimab in Nonhematologic neoplasms, head and neck squamous cell carcinoma (HNSCC), nasopharyngeal carcinoma (NPC) and 11 more, sponsored by Peking University Cancer Hospital & Institute. Primary endpoints: Objective response rate, Maximum tolerated dose and 1 more. Planned start Sep 2021; status: not yet recruiting.
02
Drugs
DN1508052toripalimab
03
Conditions
Nonhematologic neoplasmshead and neck squamous cell carcinoma (HNSCC)nasopharyngeal carcinoma (NPC)gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on ChiCTR2200064196.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200064196.